207 related articles for article (PubMed ID: 22041137)
1. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters.
Kiyotani K; Mushiroda T; Nakamura Y; Zembutsu H
Drug Metab Pharmacokinet; 2012; 27(1):122-31. PubMed ID: 22041137
[TBL] [Abstract][Full Text] [Related]
2. [Advances in the research of pharmacogenomics of tamoxifen].
Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of tamoxifen therapy.
Brauch H; Mürdter TE; Eichelbaum M; Schwab M
Clin Chem; 2009 Oct; 55(10):1770-82. PubMed ID: 19574470
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacogenetics and potential application in personalized medicine.
Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
[TBL] [Abstract][Full Text] [Related]
5. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
[TBL] [Abstract][Full Text] [Related]
6. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1).
Teft WA; Mansell SE; Kim RB
Drug Metab Dispos; 2011 Mar; 39(3):558-62. PubMed ID: 21148080
[TBL] [Abstract][Full Text] [Related]
7. Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Binkhorst L; Mathijssen RH; Jager A; van Gelder T
Cancer Treat Rev; 2015 Mar; 41(3):289-99. PubMed ID: 25618289
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of anti-estrogen treatment of breast cancer.
Del Re M; Michelucci A; Simi P; Danesi R
Cancer Treat Rev; 2012 Aug; 38(5):442-50. PubMed ID: 21917382
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?
Del Re M; Citi V; Crucitta S; Rofi E; Belcari F; van Schaik RH; Danesi R
Pharmacol Res; 2016 May; 107():398-406. PubMed ID: 27060675
[TBL] [Abstract][Full Text] [Related]
10. The risk of recurrence in breast cancer patients treated with tamoxifen: polymorphisms of CYP2D6 and ABCB1.
Teh LK; Mohamed NI; Salleh MZ; Rohaizak M; Shahrun NS; Saladina JJ; Shia JK; Roslan H; Sood S; Rajoo TS; Muniandy SP; Henry G; Ngow HA; Hla U KT; Din J
AAPS J; 2012 Mar; 14(1):52-9. PubMed ID: 22183189
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.
Cronin-Fenton DP; Damkier P
Adv Pharmacol; 2018; 83():65-91. PubMed ID: 29801584
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.
Sutiman N; Lim JSL; Muerdter TE; Singh O; Cheung YB; Ng RCH; Yap YS; Wong NS; Ang PCS; Dent R; Schroth W; Schwab M; Khor CC; Chowbay B
Clin Pharmacokinet; 2016 Oct; 55(10):1239-1250. PubMed ID: 27098059
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes.
Wang T; Zhou Y; Cao G
Eur J Clin Pharmacol; 2021 Aug; 77(8):1095-1111. PubMed ID: 33515076
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
Higgins MJ; Rae JM; Flockhart DA; Hayes DF; Stearns V
J Natl Compr Canc Netw; 2009 Feb; 7(2):203-13. PubMed ID: 19200418
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data.
Kruger B; Shamley D; Soko ND; Dandara C
Clin Transl Sci; 2024 Mar; 17(3):e13761. PubMed ID: 38476074
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.
Cronin-Fenton DP; Damkier P; Lash TL
Future Oncol; 2014 Jan; 10(1):107-22. PubMed ID: 24328412
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
20. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
